{"id":27096,"date":"2022-08-05T15:45:00","date_gmt":"2022-08-05T07:45:00","guid":{"rendered":"https:\/\/flcube.com\/?p=27096"},"modified":"2025-02-17T15:48:00","modified_gmt":"2025-02-17T07:48:00","slug":"innovent-biologics-q2-2022-revenues-surpass-rmb-1-billion-seven-products-approved","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=27096","title":{"rendered":"Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved"},"content":{"rendered":"\n

Innovent Biologics Inc. (HKG: 1801<\/a>) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab), HALPRYZA (Rituximab biosimilar), Pemazyre (pemigatinib), olverembatinib, and Cyramza (ramucirumab).<\/p>\n\n\n\n

Financial Performance<\/strong>
Despite COVID-19 disruptions in certain cities and regions affecting sales, Innovent has maintained growth momentum across its product portfolio. Tyvyt received new indication approvals for first-line esophageal cancer and first-line gastric cancer in June 2022, following the inclusion of three earlier indications on the National Reimbursement Drug List (NRDL). Other products also continued to show growth.<\/p>\n\n\n\n

Product Pipeline<\/strong>
Innovent boasts an innovative product pipeline consisting of 32 prospective drug products covering cancer, metabolic diseases, and autoimmune diseases. Among these, seven products have marketing approvals, three are awaiting regulatory decisions, three are undergoing Phase III or pivotal clinical studies, and 19 are at the pre-clinical stage.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[43,27,910,198,18],"class_list":["post-27096","post","type-post","status-publish","format-standard","hentry","category-company","tag-biosimilars","tag-finanical-reports","tag-hkg-1801","tag-innovent-biologics","tag-pd-1-l1"],"yoast_head":"\nInnovent Biologics' Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab), HALPRYZA (Rituximab biosimilar), Pemazyre (pemigatinib), olverembatinib, and Cyramza (ramucirumab).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=27096\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics' Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=27096\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-05T07:45:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-17T07:48:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27096#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27096\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved\",\"datePublished\":\"2022-08-05T07:45:00+00:00\",\"dateModified\":\"2025-02-17T07:48:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27096\"},\"wordCount\":173,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"Finanical Reports\",\"HKG: 1801\",\"Innovent Biologics\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=27096#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27096\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=27096\",\"name\":\"Innovent Biologics' Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-08-05T07:45:00+00:00\",\"dateModified\":\"2025-02-17T07:48:00+00:00\",\"description\":\"Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab), HALPRYZA (Rituximab biosimilar), Pemazyre (pemigatinib), olverembatinib, and Cyramza (ramucirumab).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27096#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=27096\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27096#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics' Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved - Insight, China's Pharmaceutical Industry","description":"Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab), HALPRYZA (Rituximab biosimilar), Pemazyre (pemigatinib), olverembatinib, and Cyramza (ramucirumab).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=27096","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics' Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=27096","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-08-05T07:45:00+00:00","article_modified_time":"2025-02-17T07:48:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=27096#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=27096"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved","datePublished":"2022-08-05T07:45:00+00:00","dateModified":"2025-02-17T07:48:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=27096"},"wordCount":173,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","Finanical Reports","HKG: 1801","Innovent Biologics","PD-1\/L1"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=27096#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=27096","url":"https:\/\/flcube.com\/?p=27096","name":"Innovent Biologics' Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-08-05T07:45:00+00:00","dateModified":"2025-02-17T07:48:00+00:00","description":"Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab), HALPRYZA (Rituximab biosimilar), Pemazyre (pemigatinib), olverembatinib, and Cyramza (ramucirumab).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=27096#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=27096"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=27096#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27096"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27096\/revisions"}],"predecessor-version":[{"id":27097,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27096\/revisions\/27097"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}